Navigation Links
Angiotech appoints Hank McKinnell to its Board of Directors
Date:5/13/2008

VANCOUVER, May 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Dr. Hank McKinnell to its Board of Directors.

Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc. He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and the Lead Director of the Board of Directors of Moody's Corporation.

"We are honoured that Dr. McKinnell has agreed to join our Board of Directors," said Dr. William Hunter, President and CEO of Angiotech. "With his history and experience in many roles at Pfizer, including as Chairman and CEO, Dr. McKinnell brings the deep industry knowledge and extraordinary leadership qualities that we will need to facilitate our continued evolution into a significant, multinational, operating business in the life sciences sector."

Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years, held positions of increasing responsibility around the world, including service as President of Pfizer Asia. In 1984, Dr. McKinnell relocated to New York, where he served as Vice President-Strategic Planning, Chief Financial Officer, President-Pfizer Medical Device Group, President-Pfizer Pharmaceuticals Group, and President and Chief Operating Officer. He was named Chairman and Chief Executive officer in 2001 and served in this role until his retirement in the second half of 2006.

Dr. McKinnell is the Chairman Emeritus of the Business Roundtable, an association of the CEOs of America's largest companies, the Pharmaceutical Research Manufacturers A
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Angiotech to participate in Bank of America Health Care Conference
2. Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
3. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
4. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
5. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
6. Angiotech announces director resignation
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
9. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
10. Angiotech to participate in Lehman Brothers Healthcare Conference
11. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Cell Culture Market 2014-2018" report to their offering.  ... Cell culture is the in vitro growth of plant ... cell studies, and biopharmaceutical production. Cell culture is a ... culture instruments and cell culture consumables are necessary for ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus Group ... regulatory and ethical review services for clinical research, ... Formerly a division of Richmond, VA ... leading biosafety and biosecurity consulting firm in ... addition, WCG,s biosafety division – WCG Biosafety™ – ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
Breaking Biology Technology:Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2
... Inc. (Amex:,SGN) announced that it has filed its Form ... of trading of its common stock,on the American Stock ... trade on AMEX will be Friday, September 12, 2008.,Signalife ... for,quotation on both the Over-The-Counter Bulletin Board and the ...
... Takeda San Francisco Inc.,announced today that Gregory Landes, ... antibody research. Dr. Landes will be responsible for,directing ... Takeda,s antibody IND engine and center of excellence ... experience in the biopharmaceutical,industry and is a great ...
... Sept. 8 NovaVision today announced,that the company ... AdvaMed,2008: The MedTech Conference (http://www.advamed2008.com ), on ... the presentation, which falls in the "Next Generation" ... officer of,NovaVision, will address the increasing use of ...
Cached Biology Technology:Signalife Announces Anticipated Date of Transition to OTCBB 2Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research 2NovaVision CEO Named Presenter at the AdvaMed 2008 Conference 2
(Date:7/24/2014)... new study has identified two factors that characterize ... the production of highly qualified physics teachers. Specifically, ... champion physics teacher education in combination with institutional ... remain viable. Science, Technology, Engineering and Math (STEM) ... the study points the way for institutions seeking ...
(Date:7/24/2014)... 2014 Some sticky research out of York University ... certain species of toxic grass fungus: moose saliva (yes ... Biology Letters , "Ungulate saliva inhibits a grassendophyte mutualism" ... red fescue grass (which hosts a fungus called epichlo ... fungus growth and less toxicity. , "Plants have evolved ...
(Date:7/24/2014)... Albert Einstein College of Medicine of Yeshiva University ... Foundation for Parkinson,s Research to translate a basic science ... discovery project will test chemical compounds on a newly ... that acts on an underlying cause of the disease. ... people manage their symptoms, we are eager to stop ...
Breaking Biology News(10 mins):Creating sustainable STEM teacher preparation programs 2Moose drool inhibits growth of toxic fungus: York U research 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... of the most recent, popular supplements for athletes looking to ... acid called L-arginine. The reason for its popularity ... physiology. "First, L-arginine is a precursor for nitric oxide ... may aid the delivery of important nutrients to working muscles ...
... published this month in the Journal of the American ... Science Center at San Antonio have pinpointed the cancer-fighting potential ... Susan Mooberry, Ph.D., leader of the Experimental Development Therapeutics Program ... of pharmacology at the UT Health Science Center, has been ...
... Researchers at King,s College London have discovered how one ... pave the way for less harmful pain relief medications to ... in the US and Asia as acetaminophen, is a widely-used ... as cold and flu remedies. Although discovered in the ...
Cached Biology News:L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Bat plant could give some cancers a devil of a time 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 2First study to reveal how paracetamol works could lead to less harmful pain relief medicines 3
...
...
Removes polysaccharide and phenolic inhibitors of PCR; yields DNA greater than 50 kb in length...
Sf9 Insect Cells (Frozen) in Max-XP Medium...
Biology Products: